DE69333856D1 - Gentechnologisch abgeschwächte virus - Google Patents

Gentechnologisch abgeschwächte virus

Info

Publication number
DE69333856D1
DE69333856D1 DE69333856T DE69333856T DE69333856D1 DE 69333856 D1 DE69333856 D1 DE 69333856D1 DE 69333856 T DE69333856 T DE 69333856T DE 69333856 T DE69333856 T DE 69333856T DE 69333856 D1 DE69333856 D1 DE 69333856D1
Authority
DE
Germany
Prior art keywords
virus
alterations
replication
viral
coding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69333856T
Other languages
English (en)
Other versions
DE69333856T2 (de
Inventor
Peter Palese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of DE69333856D1 publication Critical patent/DE69333856D1/de
Application granted granted Critical
Publication of DE69333856T2 publication Critical patent/DE69333856T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69333856T 1992-04-14 1993-04-13 Gentechnologisch abgeschwächter Virus Expired - Fee Related DE69333856T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86859692A 1992-04-14 1992-04-14
US868596 1992-04-14
PCT/US1993/003615 WO1993021306A1 (en) 1992-04-14 1993-04-13 Genetically engineered attenuated viruses

Publications (2)

Publication Number Publication Date
DE69333856D1 true DE69333856D1 (de) 2005-09-22
DE69333856T2 DE69333856T2 (de) 2006-05-18

Family

ID=25351967

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69333856T Expired - Fee Related DE69333856T2 (de) 1992-04-14 1993-04-13 Gentechnologisch abgeschwächter Virus

Country Status (10)

Country Link
EP (2) EP0636172B1 (de)
CN (1) CN1065912C (de)
AT (1) ATE302277T1 (de)
AU (1) AU687738B2 (de)
CA (1) CA2118234A1 (de)
DE (1) DE69333856T2 (de)
ES (1) ES2247584T3 (de)
IL (2) IL105379A (de)
WO (1) WO1993021306A1 (de)
ZA (1) ZA932588B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995008634A1 (en) * 1993-09-20 1995-03-30 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Method for generating influenza a viruses bearing attenuating mutations in internal protein genes
JP2000517194A (ja) * 1996-09-27 2000-12-26 アメリカン・サイアナミド・カンパニー モノネガビラレス（Ｍｏｎｏｎｅｇａｖｉｒａｌｅｓ）と称される目のウイルスにおける弱毒化の原因となる３’ゲノムプロモーター領域およびポリメラーゼ遺伝子の突然変異
US6884414B1 (en) 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
ES2526191T3 (es) 2002-04-26 2015-01-08 Medimmune, Llc Método para producir virus influenza B infeccioso en cultivo celular
EP1633312A4 (de) 2003-06-16 2012-09-26 Medimmune Llc Influenza-hämagglutinin- und neuraminidase-varianten
JP4771959B2 (ja) 2003-12-23 2011-09-14 メディミューン，エルエルシー インフルエンザウイルス作製のための多重プラスミド系
US7527800B2 (en) 2004-05-25 2009-05-05 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
WO2006098901A2 (en) 2005-03-08 2006-09-21 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
EP2614836A3 (de) 2005-10-17 2013-10-23 MedImmune, LLC Schnell wachsender reassortanter Influenza-A-Virus
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
EP2049662A4 (de) 2006-07-21 2009-12-30 Medimmune Llc Verfahren und zusammensetzungen zur erhöhung des replikationsvermögens eines influenza-virus
KR101586971B1 (ko) 2006-08-09 2016-02-22 메디뮨 엘엘씨 인플루엔자 헤마글루티닌 및 뉴라미니다제 변이체
ES2523587T3 (es) 2007-06-18 2014-11-27 Medimmune, Llc Virus influenza B que tienen alteraciones en el polipéptido hemaglutinina
RU2523587C2 (ru) 2008-07-11 2014-07-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютинина и нейрамидазы вируса гриппа
AU2010213966B2 (en) 2009-02-12 2015-01-22 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
JP5876036B2 (ja) * 2010-05-21 2016-03-02 ノバルティス アーゲー インフルエンザウイルス再集合方法
CN102816781B (zh) * 2011-06-10 2016-01-20 中国疾病预防控制中心病毒病预防控制所 一种辛德毕斯病毒xj-160缺陷型复制子及其构建方法和应用
CN106939355A (zh) * 2017-03-01 2017-07-11 苏州系统医学研究所 一种流感病毒弱毒活疫苗毒株的筛选和鉴定方法
CN114732822B (zh) * 2019-03-13 2023-06-30 中国人民解放军军事科学院军事医学研究院 氨基葡萄糖及其衍生物作为抗病毒药物的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166057A (en) * 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems

Also Published As

Publication number Publication date
EP1473361A2 (de) 2004-11-03
CN1082606A (zh) 1994-02-23
EP0636172A1 (de) 1995-02-01
EP0636172B1 (de) 2005-08-17
IL192972A0 (en) 2009-02-11
CN1065912C (zh) 2001-05-16
ATE302277T1 (de) 2005-09-15
ZA932588B (en) 1993-11-02
IL105379A0 (en) 1993-08-18
ES2247584T3 (es) 2006-03-01
IL105379A (en) 2008-12-29
WO1993021306A1 (en) 1993-10-28
AU4289393A (en) 1993-11-18
DE69333856T2 (de) 2006-05-18
CA2118234A1 (en) 1993-10-28
AU687738B2 (en) 1998-03-05
EP0636172A4 (de) 1997-05-21
EP1473361A3 (de) 2004-11-17

Similar Documents

Publication Publication Date Title
IL192972A0 (en) Genetically engineered attenuated influenza viruses and methods for preparation thereof
ATE261312T1 (de) Methode zur induktion mit immunantwort mittels expression eines heterologen immunogens in lebenden venezulanischen pferde-encephalitisviren
ATE234361T1 (de) Virale amplifikation rekombinanter boten-rna in transgenen pflanzen
EP1098961A4 (de) Interferon, das genetisch veränderte, attenuierte viren induziert
NZ335000A (en) Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
DE3850683T2 (de) Hybrides RNS-Virus.
DK0550553T3 (da) Viral defekt vaccine fremstillet af en transkomplementerende cellelinie
ATE470704T1 (de) Rekombinantes sendai-virus
NZ219002A (en) Method of modifying plant virus by pre-transforming plant genome
ATE241994T1 (de) Hsv-mutant-1716 zur behandlung von mesotheliomen
DE3381566D1 (de) Hepatitis-b-virus-gen enthaltendes rekombinantes plasmid, mit diesem rekombinanten plasmid transformierte hefe und herstellung von hepatitis-b-virus-oberflaechenantigen.
DE69028951T2 (de) Oligonukleotiden-Sequenzen zur Amplifizierung von HIV-2 und SIV Retrovirusgenomen, ihre Verwendung zur In-vitro-Diagnostik von durch diese Viren verursachten Infektionen
EP0228036A3 (de) Verfahren zur Herstellung von spezifischen Polypeptiden in virusinfizierten Insektzellen und daraus isolierte Polypeptide
FI890116A (fi) Icke-reverterande rna-virus.
IL99232A0 (en) Methods for producing rna viruses from cdna
DE69332678D1 (en) Synthetische promotoren von herpes simplex virus
CA2408786A1 (en) Retroviral vectors comprising an enhanced 3' transcription termination structure
ATE347605T1 (de) Verfahren zur genetischen veränderung einer viralen wildtyp-sequenz
FI893346A0 (fi) Icke-reverterande rna-virus.
RU93049647A (ru) Вирус насекомых, способ получения вируса
ATE115626T1 (de) Verfahren zur herstellung von fremdprotein in escherichia coli.
TH33841A (th) รีคอมบิแนนท์เอวิพอคซ์ไวรัส การเพาะเลี้ยงเซลล์ที่ติดเชื้อไวรัสนี้ และวัคซีนสำหรับสัตว์ปีกที่อนุพัทธ์จากไวรัสนี้
RU93005232A (ru) Вирусы, применение вирусов, вакцина, способ получения вируса
TH13474A (th) รีคอมบิแนนท์ varicella - zoster virus และขบวนการสร้าง
TH13474EX (th) รีคอมบิแนนท์ varicella - zoster virus และขบวนการสร้าง

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee